Beauty Health (SKIN)
NASDAQ:SKIN
SKIN Stock Chart & Stats
$0.80
-$0.07(-3.95%)
At close: 4:00 PM EST
$0.80
-$0.07(-3.95%)
Day’s Range― - ―
52-Week Range$0.78 - $2.69
Previous CloseN/A
Volume138.49K
Average Volume (3M)1.04M
Market Cap
$102.88M
Enterprise Value$248.88M
Total Cash (Recent Filing)$232.70M
Total Debt (Recent Filing)$378.70M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
May 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding127,773,050
10 Day Avg. Volume926,645
30 Day Avg. Volume1,036,656
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.88
Price to Sales (P/S)0.58
P/FCF Ratio4.72
Enterprise Value/Market Cap2.42
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda6.67
Forecast
1Y Price Target
$1.82Price Target Upside127.50% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$306.66M
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityA strong cash balance combined with low capital expenditure needs gives flexibility to fund strategic priorities and capture operating leverage as current investments conclude.
Margin ExpansionReduced operating expenses drove notable expansion in adjusted profit margins, improving profitability despite pressure on overall sales.
Revenue ResilienceRevenue decline was milder than analyst expectations, driven by resilient demand for consumable products and a smaller-than-expected drop in delivery system sales.
Bears Say
Capital Equipment DemandMacro-driven weakness in capital equipment ordering could temper near-term revenue and earnings growth as customers delay new device purchases.
Delivery Systems And China ExposureDelivery system revenues were pressured by a weak macro environment and softness in China, which weighed on new device placements and associated usage.
Visibility And Reinvestment RiskLimited visibility into consistent improvement in new device placements and management's choice to reinvest margins raise uncertainty about the timing of a sustained recovery in revenue and utilization.
Beauty Health News
SKIN FAQ
What was Beauty Health’s price range in the past 12 months?
Beauty Health lowest stock price was $0.78 and its highest was $2.69 in the past 12 months.
What is Beauty Health’s market cap?
Beauty Health’s market cap is $102.88M.
When is Beauty Health’s upcoming earnings report date?
Beauty Health’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Beauty Health’s earnings last quarter?
Beauty Health released its earnings results on Mar 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.048 by -$0.012.
Is Beauty Health overvalued?
According to Wall Street analysts Beauty Health’s price is currently Undervalued.
Does Beauty Health pay dividends?
Beauty Health does not currently pay dividends.
What is Beauty Health’s EPS estimate?
Beauty Health’s EPS estimate is -0.07.
How many shares outstanding does Beauty Health have?
Beauty Health has 127,773,050 shares outstanding.
What happened to Beauty Health’s price movement after its last earnings report?
Beauty Health reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.048. Following the earnings report the stock price went up 19.811%.
Which hedge fund is a major shareholder of Beauty Health?
Currently, no hedge funds are holding shares in SKIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.82 (127.50% Upside)
$1.82 (127.50% Upside)
Hedge Fund Trend
Decreased
By 604.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.85%
12-Months-Change
Fundamentals
Return on Equity
-19.78%
Trailing 12-Months
Asset Growth
-28.01%
Trailing 12-Months
Company Description
Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
SKIN Company Deck
SKIN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of clear operational and profitability improvements (notably strong adjusted EBITDA growth, margin expansion, operating cash generation, and a large installed base) alongside persistent top-line challenges (approximately 10% FY revenue decline, device/capital equipment weakness, APAC/China transition and a sizable cash reduction tied to debt repurchases). Management framed 2026 as an execution year to stabilize utilization, invest in sales/marketing/innovation, and drive a return to growth in 2027. Given the scale of margin and EBITDA recovery and strategic actions to unlock installed-base economics, the positives around profitability and structural positioning outweigh the near-term revenue and regional challenges.View all SKIN earnings summariesSKIN Stock 12 Month Forecast
Average Price Target
$1.82
▲(127.50% Upside)
Technical Analysis
Ownership Overview
14.47% Insiders
11.40% Mutual Funds
22.49% Other Institutional Investors
43.93% Public Companies and
Individual Investors